2. Hindricks G., Potpara T., Dagres N. et al. 2020 ESC Guidelines for the diagnosis and management ofatrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery(EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the EuropeanSociety of Cardiology (ESC) Developed with the special contribution of the European Heart RhythmAssociation (EHRA) of the ESC. Eur Heart J. 2020; ehaa612. doi: 10.1093/eurheartj/ehaa612.

3. Lip G.Y., Frison L., Halperin J.L., Lane D.A. Comparative validation of a novel risk score for predictingbleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension,Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly,Drugs/Alcohol Concomitantly) scoreJ Am Coll Cardiol. 2011; 57(2): 173–80. doi: 10.1016/j.jacc.2010.09.024.

4. Granger C.B., Alexander J.H., McMurray J.J.V. et al. (ARISTOTLE Committees and Investigators).Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11): 981–92. doi:10.1056/NEJMoa1107039.

5. Connolly S.J., Eikelboom J., Joyner C. et al. (AVERROES Steering Committee Investigators).Apixaban in patients with atrial fibrillation. N Engl J Med. 2011; 364(9): 806–17. doi: 10.1056/NEJMoa1007432.

6. Reilly P.A., Lehr T., Haertter S. et al. (RE-LY Investigators). The effect of dabigatran plasmaconcentrations and patient characteristics on the frequency of ischemic stroke and major bleeding inatrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term AnticoagulationTherapy). J Am Coll Cardiol. 2014; 63(4): 321–28. doi: 10.1016/j.jacc.2013.07.104.

7. Bansilal S., Bloomgarden Z., Halperin J.L. et al. (ROCKET AF Steering Committee and Investigators).Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: theRivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism forPrevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). Am Heart J. 2015;170(4): 675–82.e8. doi: 10.1016/j.ahj.2015.07.006.

8. Ruff C.T., Giugliano R.P., Braunwald E. et al. Association between edoxaban dose, concentration, antiFactor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGEAF-TIMI 48 trial. Lancet. 2015; 385(9984): 2288–95. doi: 10.1016/S0140-6736(14)61943-7.